The Boehringer Ingelheim Foundation is providing 600,000 Euros in funding for basic research into new approaches to the treatment of liver fibrosis and fatty liver hepatitis.

Cross-species BBB-penetrant IV-delivered AAV gene therapy provides broad and robust CNS tau lowering in tauopathy mouse models and non-human primate (#559). Hechen Bao, Ph.D., Scientist II, ...

Strand Therapeutics Inc., the programmable mRNA company developing curative therapies for cancer and beyond, will present preclinical data from its STX-003 program at the 2025 annual meetings of the ...

Details for the poster presentation are as follows: Presentation Title: An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies Poster ...

A bill introduced in Minnesota highlights the dilemma of explaining vaccine technology to patients and the general public.

The US Food and Drug Administration (FDA) has granted rare paediatric disease and orphan drug designations for IN013, Innorna ...

Infectious diseases continue to pose major global health threats, with rising cases of antimicrobial resistance and the constant emergence of new pathogens.

Innorna Co. Ltd.’s investigational mRNA therapy, IN-013, has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of Wilson disease.

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.